AZE logo

Azelis Group NV Stock Price

ENXTBR:AZE Community·€2.7b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 20 Fair Values set on narratives written by author

AZE Share Price Performance

€11.27
-2.02 (-15.20%)
€13.11
Fair Value
€11.27
-2.02 (-15.20%)
14.1% undervalued intrinsic discount
€13.11
Fair Value
Price €11.27
AnalystConsensusTarget €13.11
AnalystLowTarget €10.00
AnalystHighTarget €16.00

AZE Community Narratives

·
Fair Value €13.11 14.1% undervalued intrinsic discount

Recovery Will Likely Emerge After Industry Pressures Ease In 2026

0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
·
Fair Value €10 12.7% overvalued intrinsic discount

Specialty Chemicals Will Endure Market Headwinds With Gradual Relief

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
·
Fair Value €16 29.6% undervalued intrinsic discount

Rising Demand For Specialty Chemicals Will Fuel Market Expansion

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
€16
29.6% undervalued intrinsic discount
Revenue
5.74% p.a.
Profit Margin
5.1%
Future PE
20.61x
Price in 2029
€20.98

Trending Discussion

No trending discussion available.

Updated Narratives

AZE logo

AZE: Margin Recovery And Dividend Visibility Will Support Repriced Risk Outlook

Fair Value: €13.11 14.1% undervalued intrinsic discount
9 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
AZE logo

AZE: Fairly Priced Outlook Will Test Execution And Dividend Support

Fair Value: €10 12.7% overvalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
AZE logo

AZE: Dividend Policy And Buybacks Will Support A More Constructive Outlook

Fair Value: €16 29.6% undervalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Adequate balance sheet and fair value.

2 Risks
2 Rewards

Azelis Group NV Key Details

€4.1b

Revenue

€3.2b

Cost of Revenue

€955.8m

Gross Profit

€843.0m

Other Expenses

€112.8m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
0.46
23.21%
2.74%
58.7%
View Full Analysis

About AZE

Founded
1996
Employees
4000
CEO
Anna Bertona
WebsiteView website
www.azelis.com

Azelis Group NV engages in the distribution of specialty chemicals and food ingredients. The company provides specialty chemical products used in the life sciences, such as personal care, home care, industrial cleaning, pharmaceuticals, healthcare, food and nutrition, animal nutrition, agricultural environmental, flavours and fragrances, and nutraceuticals solutions; and industrial chemicals industry, including CASE, advanced materials and additives, lubricants, metalworking fluids, electronics, essential and fine chemicals, textiles, leather, and paper markets. It operates in Europe, Middle East, and Africa, as well as the Americas and the Asia-Pacific. Azelis Group NV was founded in 1996 and is headquartered in Antwerp, Belgium.

Recent AZE News & Updates

Narrative Update Jul 30

AZE: Margin Recovery And Dividend Visibility Will Support Repriced Risk Outlook

Analysts have nudged their fair value estimate for Azelis Group higher to €13.11 from €12.48, reflecting a slightly more constructive view on revenue growth, profit margins and risk after recent price target increases from €7.50 to €10.50 and from €10.50 to €12. The latest ratings suggest that key risks are now better reflected in the share price.
Narrative Update Jul 14

AZE: Fairly Priced Outlook Will Test Execution And Dividend Support

Analysts now see Azelis Group's fair value edging up from €9.50 to €10.00, in line with recent price target increases to €10.50 and €12 that reflect a view that key risks are already reflected in the stock. Analyst Commentary Recent research on Azelis Group points to a more balanced stance, with price targets in a relatively tight range and an emphasis on how much risk is already reflected in the current share price.

Recent updates

No updates